New-generation JAK inhibitors: how selective can they be?

Affiliations

¹ Department of Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway.
² Department of Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway. Electronic address: t.k.kvien@medisin.uio.no.

Comment

Guro L Goll et al. Lancet. 2018.

. 2018 Jun 23;391(10139):2477-2478.

doi: 10.1016/S0140-6736(18)31325-4. Epub 2018 Jun 13.

¹ Department of Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway.
² Department of Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway. Electronic address: t.k.kvien@medisin.uio.no.

No abstract available

Comment on

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS. Burmester GR, et al. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18. Lancet. 2018. PMID: 29908669 Clinical Trial.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL. Genovese MC, et al. Lancet. 2018 Jun 23;391(10139):2513-2524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18. Lancet. 2018. PMID: 29908670 Clinical Trial.